T1	p 325 377	of 95 patients with atherosclerotic disease . During
T2	i 58 70	lipid esters
T3	i 78 102	lipid-lowering treatment
T4	i 108 142	diet , clofibrate and niceritrol .
T5	i 187 197	clofibrate
T6	i 263 275	lipid esters
T7	i 478 527	clofibrate or niceritrol , a nicotinic acid ester
T8	i 647 679	diet , clofibrate and niceritrol
T9	i 778 784	esters
T10	i 938 979	and monounsaturated fatty acids secreased
T11	i 988 1015	polyunsaturated fatty acids
T12	i 1089 1094	fatty
T13	i 1268 1278	clofibrate
T14	i 1360 1370	Clofibrate
T15	i 1418 1439	monounsaturated fatty
T16	i 1597 1605	linoleic
T17	i 1738 1744	esters
T18	i 1862 1873	fatty acids
T19	i 1905 1915	clofibrate
T20	i 1961 1981	clofibrate treatment
T21	i 2026 2046	polyunsaturated fats
T22	i 2099 2120	monounsaturated fatty
T23	i 2147 2153	esters
T24	i 2206 2221	polyunsaturated
T25	i 2236 2247	fatty acids
T26	i 2283 2293	clofibrate
T27	i 2347 2362	polyunsaturated
T28	o 27 31	acid
T29	o 51 63	plasma lipid
T30	o 160 183	proportion of linoleate
T31	o 187 197	clofibrate
T32	o 232 248	acid composition
T33	o 256 268	plasma lipid
T34	o 706 784	serum lipid reductions . The fatty acid composition in the plasma lipid esters
T35	o 856 878	of dietary adherence .
T36	o 964 979	acids secreased
T37	o 1004 1015	fatty acids
T38	o 1045 1050	ratio
T39	o 1095 1106	acids ( P/S
T40	o 1145 1158	triglycerides
T41	o 1331 1380	the fatty acid composition . Clofibrate treatment
T42	o 1418 1447	monounsaturated fatty acids ,
T43	o 1459 1465	oleate
T44	o 1486 1538	cholesterol esters , triglycerides and phospholipids
T45	o 1586 1621	content of linoleic ( 18 : 2 ) acid
T46	o 1634 1696	cholesterol esters and triglycerides . The 18 : 2/18 : 1 ratio
T47	o 1732 1737	lipid
T48	o 1770 1779	P/S ratio
T49	o 2363 2366	fat